These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 23083823)
1. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. Flemming JA; Terrault NA Infect Dis Clin North Am; 2012 Dec; 26(4):903-15. PubMed ID: 23083823 [TBL] [Abstract][Full Text] [Related]
2. [New triple therapy in chronic hepatitis C. Increased patient chances]. Stiefelhagen P MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830 [No Abstract] [Full Text] [Related]
3. Approach to the treatment-naïve patient with HCV genotype 1 infection. Muir AJ Infect Dis Clin North Am; 2012 Dec; 26(4):893-901. PubMed ID: 23083822 [TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Pearlman BL Lancet Infect Dis; 2012 Sep; 12(9):717-28. PubMed ID: 22647717 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases]. Serfaty L Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289 [No Abstract] [Full Text] [Related]
6. [Clinical significance of measuring HCV-RNA levels in patients with chronic hepatitis C by IFN treatment, including combination therapy with ribavirin]. Kakumu S Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):507-10. PubMed ID: 15359851 [No Abstract] [Full Text] [Related]
7. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876 [TBL] [Abstract][Full Text] [Related]
8. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]. Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z; Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266 [TBL] [Abstract][Full Text] [Related]
9. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Trembling PM; Tanwar S; Dusheiko GM Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560 [TBL] [Abstract][Full Text] [Related]
10. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728 [TBL] [Abstract][Full Text] [Related]
11. [Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. Bruguera M; Esteban R; Forns X; Planas R; Quer JC; Solà R; Vergara M; Gastroenterol Hepatol; 2012 Nov; 35(9):667-74. PubMed ID: 22560187 [No Abstract] [Full Text] [Related]
12. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799 [TBL] [Abstract][Full Text] [Related]
14. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment. Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. Lobato CMO; Balassiano N; Hyppolito EB; Sanchez-Lermen RLP; Signorelli IV; Nicacio MYT; Firmino Filho AP; Andrade TG; Lima JMC; Arruda TA; Coutinho FS; Araujo EFDV; Esmeraldo TM; Cortez E; Capeli RLA; Matos MBM; Pessoa FSR; Oliveira HC; Arruda ÉAG; Gonçalves PL; Araújo Filho AH; Esberard EBC; Souto FJD Rev Soc Bras Med Trop; 2018; 51(1):14-20. PubMed ID: 29513836 [TBL] [Abstract][Full Text] [Related]
17. What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both? Weiland O J Hepatol; 2009 Jul; 51(1):4-7. PubMed ID: 19446915 [No Abstract] [Full Text] [Related]
18. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758 [TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination]. Niederau C MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352 [No Abstract] [Full Text] [Related]